Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells

References

• Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004; 82:249 - 93; http://dx.doi.org/10.1016/S0065-2776(04)82006-6; PMID: 14975259
   PubMed Web of Science ®Google Scholar
• Von Mensdorff-Pouilly S, Moreno M, Verheijen RH. Natural and induced humoral responses to MUC1. Cancers (Basel) 2011; 3:3073 - 103; http://dx.doi.org/10.3390/cancers3033073; PMID: 24212946
   PubMedGoogle Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323 - 37; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737; PMID: 19723653
   PubMed Web of Science ®Google Scholar
• Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003; 103:97 - 100; http://dx.doi.org/10.1002/ijc.10801; PMID: 12455059
   PubMed Web of Science ®Google Scholar
• Richards ER, Devine PL, Quin RJ, Fontenot JD, Ward BG, McGuckin MA. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 1998; 46:245 - 52; http://dx.doi.org/10.1007/s002620050484; PMID: 9690452
   PubMed Web of Science ®Google Scholar
• Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K, Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000; 161:589 - 94; http://dx.doi.org/10.1164/ajrccm.161.2.9905028; PMID: 10673204
   PubMed Web of Science ®Google Scholar
• von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000; 18:574 - 83; PMID: 10653872
   PubMed Web of Science ®Google Scholar
• Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, Livingston PO, Hilgers J, Kenemans P. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer 2001; 93:97 - 106; http://dx.doi.org/10.1002/ijc.1286; PMID: 11391628
   PubMed Web of Science ®Google Scholar
• Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RH, von Mensdorff-Pouilly S. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett 2007; 257:47 - 55; http://dx.doi.org/10.1016/j.canlet.2007.06.016; PMID: 17692456
   PubMed Web of Science ®Google Scholar
• Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004; 101:811 - 6; http://dx.doi.org/10.1073/pnas.0304146101; PMID: 14711987
   PubMed Web of Science ®Google Scholar
• Andrén O, Fall K, Andersson SO, Rubin MA, Bismar TA, Karlsson M, Johansson JE, Mucci LA. MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer 2007; 97:730 - 4; http://dx.doi.org/10.1038/sj.bjc.6603944; PMID: 17726465
   PubMed Web of Science ®Google Scholar
• Pandey JP, Li Z. The forgotten tale of immunoglobulin allotypes in cancer risk and treatment. Exp Hematol Oncol 2013; 2:6; http://dx.doi.org/10.1186/2162-3619-2-6; PMID: 23425356
   PubMedGoogle Scholar
• Schanfield MS, van Loghem E. Human immunoglobulin allotypes. In: Weir DM (ed) Handbook of Experimental Immunology. Boston: Blackwell 1986; 94.1-94.18.
   Google Scholar
• MacDonald IM, Dumble LJ, Jack I, Clunie GJ. Inhibition of whole blood antibody dependent cellular cytotoxicity by heat aggregated human IgG. J Immunol Methods 1981; 46:69 - 76; http://dx.doi.org/10.1016/0022-1759(81)90334-3; PMID: 7288199
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005 - 10; http://dx.doi.org/10.1073/pnas.0508123103; PMID: 16537476
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317 - 27; http://dx.doi.org/10.1038/nri2744; PMID: 20414205
   PubMed Web of Science ®Google Scholar
• Brüggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987; 166:1351 - 61; http://dx.doi.org/10.1084/jem.166.5.1351; PMID: 3500259
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res 2011; 17:6822 - 30; http://dx.doi.org/10.1158/1078-0432.CCR-11-1151; PMID: 21878535
   PubMed Web of Science ®Google Scholar
• Pandey JP, Kistner-Griffin E, Namboodiri AM, Black L, Jobim M. Suggestive evidence that Fc variants of IgG2 and FcγRIIa loci interact to contribute to the risk of prostate cancer. Hum Immunol 2013; 74:1656 - 8; http://dx.doi.org/10.1016/j.humimm.2013.08.280; PMID: 23994584
   PubMed Web of Science ®Google Scholar